BRPI0212137A2 - diidropteridinonas, processos para prepará-las e seu uso como composições farmacêuticas - Google Patents

diidropteridinonas, processos para prepará-las e seu uso como composições farmacêuticas

Info

Publication number
BRPI0212137A2
BRPI0212137A2 BRPI0212137A BR0212137A BRPI0212137A2 BR PI0212137 A2 BRPI0212137 A2 BR PI0212137A2 BR PI0212137 A BRPI0212137 A BR PI0212137A BR 0212137 A BR0212137 A BR 0212137A BR PI0212137 A2 BRPI0212137 A2 BR PI0212137A2
Authority
BR
Brazil
Prior art keywords
dihydropteridinones
preparing
processes
use
pharmaceutical compositions
Prior art date
Application number
BRPI0212137A
Other languages
English (en)
Inventor
Christian Eickmeier
Eckhart Bauer
Gerald Pohl
Gisela Schnapp
Jens Jürgen Quant
Martin Steegmaier
Matthias Grauert
Matthias Hoffmann
Norbert Redemann
Steffen Breitfelder
Thorsten Lehmann-Lintz
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE10143272 priority Critical
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Priority to PCT/EP2002/009728 priority patent/WO2003020722A1/de
Publication of BRPI0212137A2 publication Critical patent/BRPI0212137A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
BRPI0212137A 2001-09-04 2002-08-30 diidropteridinonas, processos para prepará-las e seu uso como composições farmacêuticas BRPI0212137A2 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE10143272 2001-09-04
PCT/EP2002/009728 WO2003020722A1 (de) 2001-09-04 2002-08-30 Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
BRPI0212137A2 true BRPI0212137A2 (pt) 2016-06-28

Family

ID=7697637

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0212137A BRPI0212137A2 (pt) 2001-09-04 2002-08-30 diidropteridinonas, processos para prepará-las e seu uso como composições farmacêuticas

Country Status (29)

Country Link
EP (1) EP1427730B1 (pt)
JP (1) JP3876254B2 (pt)
KR (1) KR100955589B1 (pt)
CN (1) CN1551881A (pt)
AR (1) AR036586A1 (pt)
AT (1) AT332898T (pt)
AU (1) AU2002337047B2 (pt)
BR (1) BRPI0212137A2 (pt)
CA (1) CA2458699C (pt)
CO (1) CO5560575A2 (pt)
DE (1) DE50207522D1 (pt)
DK (1) DK1427730T3 (pt)
EA (1) EA007062B1 (pt)
EC (1) ECSP045003A (pt)
ES (1) ES2268093T3 (pt)
HR (1) HRP20040213A2 (pt)
HU (1) HU0401293A3 (pt)
IL (2) IL160440D0 (pt)
MX (1) MXPA04002067A (pt)
MY (1) MY129751A (pt)
NO (1) NO328804B1 (pt)
NZ (1) NZ531928A (pt)
PL (1) PL369740A1 (pt)
PT (1) PT1427730E (pt)
RS (1) RS51012B (pt)
UA (1) UA76512C2 (pt)
UY (1) UY27427A1 (pt)
WO (1) WO2003020722A1 (pt)
ZA (1) ZA200401365B (pt)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60037321D1 (de) 1999-08-04 2008-01-17 Icagen Inc Benzanilide als öffner des kaliumkanals
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
JP3876265B2 (ja) * 2003-02-26 2007-01-31 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ジヒドロプテリジノン、その製造方法及び薬物形態での使用
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
JP2008510771A (ja) * 2004-08-27 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法および医薬薬剤としてのその使用
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
JP2009503014A (ja) * 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患の治療におけるジヒドロプテリジノン
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
JP5243970B2 (ja) 2006-02-14 2013-07-24 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated タンパク質キナーゼの阻害剤として有用なジヒドロジアゼピン
CN101448830A (zh) * 2006-05-19 2009-06-03 阿斯利康(瑞典)有限公司 作为抗增殖剂的二氢碟啶化合物
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
WO2008009909A1 (en) * 2006-07-17 2008-01-24 Astrazeneca Ab Pteridimones as modulators of polo-like kinase
WO2008040951A1 (en) * 2006-10-03 2008-04-10 Astrazeneca Ab Compounds
JP5513118B2 (ja) * 2006-10-19 2014-06-04 シグナル ファーマシューティカルズ,エルエルシー ヘテロアリール化合物、その組成物、及びプロテインキナーゼ阻害剤としてのそれらの使用
EP1953163A1 (en) * 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinone derivatives as PI3-kinases inhibitors
AT524472T (de) 2007-03-22 2011-09-15 Takeda Pharmaceutical Als plk1-inhibitoren geeignete substituierte pyrimidodiazepine
WO2008157235A1 (en) * 2007-06-13 2008-12-24 University Of Virginia Patent Foundation Rsk inhibitors as anti-septicemia agents
WO2009019205A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
WO2009023269A2 (en) * 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5h-pyrimido [4, 5-b[1, 4] diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
CN101917995A (zh) 2007-09-25 2010-12-15 武田药品工业株式会社 Polo样激酶抑制剂
JP5400791B2 (ja) * 2007-12-04 2014-01-29 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ジヒドロプテリジン−6−オン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用
AU2009225189B2 (en) 2008-03-11 2012-08-02 University Health Network Method of treating cancer using a neuropeptide Y 5R (NP Y5R) antagonist
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
GB0807452D0 (en) * 2008-04-24 2008-05-28 Chroma Therapeutics Ltd PLK inhibitors
US8093043B2 (en) 2008-06-04 2012-01-10 New York University β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
EP2303889A1 (en) 2008-06-18 2011-04-06 F. Hoffmann-La Roche AG Halo-substituted pyrimidodiazepines as plkl inhibitors
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
KR101787309B1 (ko) 2008-12-09 2017-10-18 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체의 조절제
CA2772253C (en) 2009-09-14 2018-02-27 Gilead Sciences, Inc. Modulators of toll-like receptors
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
MX2012003484A (es) 2009-09-25 2012-04-20 Vertex Pharma Metodos para preparar derivados de pirimidina utiles como inhibidores de proteina cinasa.
CN103492391A (zh) 2009-09-25 2014-01-01 沃泰克斯药物股份有限公司 用于制备用作蛋白激酶抑制剂的嘧啶衍生物的方法
CN106117213A (zh) 2009-10-26 2016-11-16 西格诺药品有限公司 杂芳基化合物及其合成和纯化方法
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
CA2783258A1 (en) 2009-12-23 2011-06-30 Elan Pharmaceuticals, Inc. Pteridinones as inhibitors of polo-like kinase
US20120329803A1 (en) 2010-02-17 2012-12-27 Boehringer Ingelheim International Gmbh Dihydropteridinones, method for production and use thereof
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
EA201890768A3 (ru) 2011-10-19 2018-12-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Лечение злокачественной опухоли ингибиторами tor-киназы
WO2013075083A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2785325B1 (en) 2011-12-02 2018-08-22 Signal Pharmaceuticals, LLC Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
EP2812001B1 (en) 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9006226B2 (en) 2012-02-23 2015-04-14 Boehringer Ingelheim International Gmbh Dihydropteridinones I
US8865716B2 (en) 2012-02-23 2014-10-21 Boehringer Ingelheim International Gmbh Dihydropteridinones II
US9375443B2 (en) 2012-02-24 2016-06-28 Signal Pharmaceuticals, Llc Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
WO2014113429A2 (en) 2013-01-16 2014-07-24 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
WO2014127815A1 (en) * 2013-02-21 2014-08-28 Boehringer Ingelheim International Gmbh Dihydropteridinones i
WO2014127816A1 (en) * 2013-02-21 2014-08-28 Boehringer Ingelheim International Gmbh Dihydropteridinones ii
WO2014151142A1 (en) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
KR20160002782A (ko) 2013-04-17 2016-01-08 시그날 파마소티칼 엘엘씨 암 치료용 tor 키나제 억제제 및 시티딘 유사체를 포함하는 병용 요법
TWI631950B (zh) 2013-04-17 2018-08-11 標誌製藥公司 藉二氫吡𠯤并吡𠯤治療癌症
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CN105324381A (zh) 2013-04-17 2016-02-10 西格诺药品有限公司 有关1-乙基-7-(2-甲基-6-(1H-1,2,4-三唑-3-基)吡啶-3-基)-3,4-二氢吡嗪并[2,3-b]吡嗪-2(1H)-酮的药物制剂、程序、固体形式和使用方法
TWI654979B (zh) 2013-04-17 2019-04-01 美商標誌製藥公司 使用tor激酶抑制劑組合療法以治療癌症之方法
AU2014254058B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a Dihydropyrazino-Pyrazine Compound and an androgen receptor antagonist for treating prostate cancer
BR112015026021A2 (pt) 2013-04-17 2017-07-25 Signal Pharm Llc terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
US9604939B2 (en) 2013-05-29 2017-03-28 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use
EP3019493B1 (de) * 2013-07-09 2017-06-14 Bayer Pharma Aktiengesellschaft Modifizierte bet-proteininhibitorische dihydrochinoxalinone und dihydropyridopyrazinone
EP3024327B1 (en) 2013-07-25 2019-09-04 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
WO2015023915A1 (en) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
CN103664845B (zh) * 2013-12-27 2016-02-10 湖南欧亚生物有限公司 一种Plk激酶抑制剂药物中间体7-氨基-2,3-二氢苯并呋喃-4-甲酸的制备方法
US10150756B2 (en) 2014-01-31 2018-12-11 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
NZ629860A (en) 2014-04-16 2016-01-29 Signal Pharm Llc Methods for treating cancer using tor kinase inhibitor combination therapy
NZ629877A (en) 2014-04-16 2015-12-24 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
NZ629884A (en) 2014-04-16 2016-03-31 Signal Pharm Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, and a coformer, compositions and methods of use thereof
NZ629866A (en) 2014-04-16 2015-12-24 Signal Pharm Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, and a coformer, compositions and methods of use thereof
WO2015193229A1 (de) * 2014-06-19 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe
WO2015193228A1 (de) * 2014-06-19 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit para-substituierter aromatischer amino- oder ethergruppe
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
CN106715427A (zh) 2014-07-14 2017-05-24 西格诺药品有限公司 利用取代的吡咯并嘧啶化合物、其组合物治疗癌症的方法
WO2016022902A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
MX2017003284A (es) 2014-09-16 2017-06-28 Gilead Sciences Inc Formas solidas de modulador de receptor tipo toll.
JP6373490B2 (ja) 2014-09-16 2018-08-15 ギリアード サイエンシーズ, インコーポレイテッド Toll様受容体モジュレーターを調製する方法
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
DE102017005091A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
CN109843870A (zh) 2016-10-19 2019-06-04 星座制药公司 Ezh2抑制剂的合成
WO2019126696A1 (en) * 2017-12-22 2019-06-27 Dana-Farber Cancer Institute, Inc. Nek inhibitors and methods of use
WO2019209757A1 (en) * 2018-04-24 2019-10-31 Vertex Pharmaceuticals Incorporated Pteridinone compounds and uses thereof
CN108610343A (zh) * 2018-06-12 2018-10-02 杨文思 一种用于治疗癌症的表皮生长因子受体抑制剂及其合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2645152B1 (fr) * 1989-03-30 1991-05-31 Lipha 3h-pteridinones-4, procedes de preparation et medicaments les contenant
CA2029651C (en) * 1989-11-17 2000-06-06 David D. Davey Tricyclic pteridinones and a process for their preparation
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
PL353269A1 (xx) * 1999-09-15 2003-11-03 Warner-Lambert Company Pterydynony jako inhibitory kinaz
WO2002076954A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases

Also Published As

Publication number Publication date
AR036586A1 (es) 2004-09-22
IL160440D0 (en) 2004-07-25
NO328804B1 (no) 2010-05-18
KR20040029465A (ko) 2004-04-06
CA2458699C (en) 2010-10-19
AT332898T (de) 2006-08-15
EP1427730A1 (de) 2004-06-16
JP3876254B2 (ja) 2007-01-31
EP1427730B1 (de) 2006-07-12
ES2268093T3 (es) 2007-03-16
NO20040680D0 (no) 2004-02-16
EA007062B1 (ru) 2006-06-30
IL160440A (en) 2009-09-01
NO20040680L (no) 2004-02-16
UA76512C2 (en) 2004-07-15
CA2458699A1 (en) 2003-03-13
YU27304A (sh) 2006-08-17
MY129751A (en) 2007-04-30
AU2002337047B8 (en) 2003-03-18
NZ531928A (en) 2005-10-28
JP2005501904A (ja) 2005-01-20
AU2002337047B2 (en) 2008-01-10
DE50207522D1 (de) 2006-08-24
RS51012B (en) 2010-10-31
UY27427A1 (es) 2003-03-31
ZA200401365B (en) 2005-05-27
PL369740A1 (en) 2005-05-02
MXPA04002067A (es) 2004-06-07
WO2003020722A1 (de) 2003-03-13
EA200400368A1 (ru) 2004-12-30
HU0401293A3 (en) 2008-03-28
ECSP045003A (es) 2004-04-28
KR100955589B1 (ko) 2010-04-30
CN1551881A (zh) 2004-12-01
HU0401293A2 (hu) 2004-10-28
DK1427730T3 (da) 2006-11-06
PT1427730E (pt) 2006-11-30
CO5560575A2 (es) 2005-09-30
HRP20040213A2 (en) 2005-02-28

Similar Documents

Publication Publication Date Title
DE50206264D1 (de) Verfahren zur herstellung von 1,2-dichlorethan
DE60238241D1 (de) Zusammensetzungen und verfahren für biomedizinische anwendungen
DE50211324D1 (de) Verfahren zur herstellung von polyurethanelastomeren und verwendung
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
DE60230160D1 (de) 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen
DE60219319D1 (de) Trockene hämostatische zusammensetzungen und verfahren zu ihrer herstellung
FR2824267B1 (fr) Composition cosmetique filmogene
FR2819386B1 (fr) Table pliante
DK1448195T3 (da) N-adamantylmethylderivater og mellemprodukter som farmaceutiske præparater og fremgangsmåde til fremstilling deraf
DK1280515T3 (da) Farmaceutiske sammensætninger omfattende cannabis
DE50204347D1 (de) Schere, insbesondere für chirurgische Zwecke
DE69940775D1 (de) Peptidzusammensetzung als immunogen zur allergiebehandlung.
DK1438481T3 (da) Behandlingspræparat
DE60236605D1 (de) Zusammensetzungen und deren verwendung zur behandlung von krebs
DE50212243D1 (de) Prozess zur herstellung von aryl-aryl gekoppelten verbindungen
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DK1390066T3 (da) Vaccinesammensætning
DE60226578D1 (de) Chirurgische greifvorrichtung
DE60219469D1 (de) Heterozyklische verbindungen, verfahren zu deren herstellung sowie deren verwendung als antibiotika
DE60206574D1 (de) Entnahmegefässanordnung
FR2819254B1 (fr) Nouveaux composes de la n-(phenylsulfonyl) glycine, leur procede de preparation et leur utilisation pour obtenir des compostions pharmaceutiques
DE60205388D1 (de) Poxvirus-enthaltende zusammensetzungen und verfahren zu ihrer herstellung
DE60136300D1 (de) Verfahren zur Herstellung von mikronisiertem Kollagen, und therapeutische Verwendungen
DE60236016D1 (de) Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 10A, 11A, 12A, 13A E 14A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.